+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Implantable cardioverter defibrillator: charge saver, not syncope saver!

Implantable cardioverter defibrillator: charge saver, not syncope saver!

Canadian Journal of Cardiology 26(9): E341

In patients with an implantable cardioverter defibrillator, empirical antitachycardia pacing/burst pacing (ATP) is associated with a significantly decreased rate of appropriate shocks. The use of ATP as first-line therapy in ventricular tachycardia promotes less pain and better quality of life because the number of shocks is reduced. Additionally, battery longevity is substantially increased with this strategy. Based on this, device manufacturers have developed new algorithms to optimize the use of ATP and shocks in patients with an implantable cardioverter defibrillator. The present report describes a case in which the use of one of these new algorithms was associated with a significant delay in tachycardia termination and, consequently, led to syncope.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 053732552

Download citation: RISBibTeXText

PMID: 21076727

Related references

A lip saver, a time saver, and a mind saver in cleft lip surgery. Plastic and Reconstructive Surgery 65(6): 834, 1980

Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator therapy. Journal of Cardiovascular Pharmacology and Therapeutics 15(1): 37-40, 2010

Implantable cardioverter defibrillator utilization among device recipients presenting exclusively with syncope or near-syncope. Journal Of Cardiovascular Electrophysiology. 8(10): 1087-1097, 1997

Dual-Chamber Implantable Cardioverter Defibrillator vs Single-Chamber Implantable Cardioverter Defibrillator High incidence of device and lead related complications in Dual-Chamber Implantable Cardioverter Defibrillator. Journal of the American College of Cardiology 35(2 Suppl A): 127A, 2000

High failure rate for an epicardial implantable cardioverter-defibrillator lead: Implications for long-term follow-up of patients with an implantable cardioverter-defibrillator. Journal of the American College of Cardiology 31(3): 616-622, 1998

Dual-Chamber Implantable Cardioverter-Defibrillator Selection Is Associated With Increased Complication Rates and Mortality Among Patients Enrolled in the NCDR Implantable Cardioverter-Defibrillator Registry. Yearbook of Cardiology 2012: 462-463, 2012

Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death: The Alphee Study. Yearbook of Cardiology 2012: 472-474, 2012

Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study. Circulation 124(24): 2649-2660, 2011

Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. Journal of the American College of Cardiology 58(10): 1007-1013, 2011

Incidence and Predictors of Implantable Cardioverter-Defibrillator Therapy in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Undergoing Implantable Cardioverter-Defibrillator Implantation for Primary Prevention. Yearbook of Cardiology 2012: 478-480, 2012

Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. Journal of the American College of Cardiology 58(14): 1485-1496, 2011

Implantable cardioverter-defibrillator registry risk score models for acute procedural complications or death after implantable cardioverter-defibrillator implantation. Circulation 123(19): 2069-2076, 2011

Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. Heart Rhythm 9(2): 217-224.E2, 2012

Dutch outcome in implantable cardioverter-defibrillator therapy (DO-IT): registry design and baseline characteristics of a prospective observational cohort study to predict appropriate indication for implantable cardioverter-defibrillator. Netherlands Heart Journal 25(10): 574-580, 2017

Pre-implantation implantable cardioverter defibrillator concerns and Type D personality increase the risk of mortality in patients with an implantable cardioverter defibrillator. Europace 12(10): 1446-1452, 2010